ECSP22001370A - Inhibidores de prmt5 - Google Patents

Inhibidores de prmt5

Info

Publication number
ECSP22001370A
ECSP22001370A ECSENADI20221370A ECDI202201370A ECSP22001370A EC SP22001370 A ECSP22001370 A EC SP22001370A EC SENADI20221370 A ECSENADI20221370 A EC SENADI20221370A EC DI202201370 A ECDI202201370 A EC DI202201370A EC SP22001370 A ECSP22001370 A EC SP22001370A
Authority
EC
Ecuador
Prior art keywords
overexpression
disorders
prmt5
prmt5 inhibitors
relates
Prior art date
Application number
ECSENADI20221370A
Other languages
English (en)
Inventor
Rajender Kumar Kamboj
Chaitanya Kulkarni
Dipak Lagad
Mahadeo Tryambake
Chetan Pawar
Milind Sindkhedkar
Ganesh Gudade
Prathap Nair
Venkata Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP22001370A publication Critical patent/ECSP22001370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención se refiere a análogos de nucleósidos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5.
ECSENADI20221370A 2019-06-10 2022-01-07 Inhibidores de prmt5 ECSP22001370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921022972 2019-06-10
IN201921022971 2019-06-10

Publications (1)

Publication Number Publication Date
ECSP22001370A true ECSP22001370A (es) 2022-02-25

Family

ID=71670318

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20221370A ECSP22001370A (es) 2019-06-10 2022-01-07 Inhibidores de prmt5

Country Status (27)

Country Link
US (1) US20220315589A1 (es)
EP (1) EP3980417B1 (es)
JP (1) JP2022536337A (es)
KR (1) KR20220019781A (es)
CN (1) CN114026094A (es)
AU (1) AU2020293021A1 (es)
BR (1) BR112021024999A2 (es)
CA (1) CA3141748A1 (es)
CL (1) CL2021003292A1 (es)
CO (1) CO2022000061A2 (es)
CR (1) CR20220010A (es)
DK (1) DK3980417T3 (es)
EC (1) ECSP22001370A (es)
ES (1) ES2967457T3 (es)
FI (1) FI3980417T3 (es)
HR (1) HRP20231673T1 (es)
HU (1) HUE064493T2 (es)
IL (1) IL288401A (es)
LT (1) LT3980417T (es)
MX (1) MX2021015262A (es)
PE (1) PE20230245A1 (es)
PL (1) PL3980417T3 (es)
PT (1) PT3980417T (es)
RS (1) RS64972B1 (es)
SI (1) SI3980417T1 (es)
WO (1) WO2020250123A1 (es)
ZA (1) ZA202109573B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
WO2023278564A1 (en) * 2021-07-02 2023-01-05 Mirati Therapeutics, Inc. Aminopyridine-based mta-cooperative prmt5 inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
BRPI0820972A2 (pt) 2007-12-11 2018-08-14 Hoffmann La Roche compostos inibidores de estearoil-coa dessaturase 1, processo para a sua preparação, composição farmacêutica que compreende, uso dos mesmos e método para o tratamento e profilaxia de obesidade.
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
LT3050874T (lt) 2008-11-14 2019-04-10 Merial Inc. Enantiomeriškai praturtinti arilazol-2-ilo cianetilamino paraziticidiniai junginiai
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
BR112012033770A2 (pt) 2010-06-30 2016-11-22 Fujifilm Corp novo derivado de nicotinamida ou sal do mesmo
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN104662018B (zh) * 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
CN106488910B (zh) 2013-10-10 2020-07-31 亚瑞克西斯制药公司 Kras g12c的抑制剂
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
ES2869374T3 (es) 2014-06-25 2021-10-25 Glaxosmithkline Ip Dev Ltd Sales cristalinas de (S)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidin-4-carboxamida
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2017530940A (ja) 2014-08-04 2017-10-19 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
BR112017017396A2 (pt) 2015-02-24 2018-04-03 Pfizer derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3596051B1 (en) 2017-03-13 2022-04-27 Impetis Biosciences Ltd. Fused bicyclic compounds, compositions and applications thereof
HUE059945T2 (hu) * 2017-12-13 2023-01-28 Lupin Ltd Helyettesített biciklusos heterociklusos vegyületek, mint PRMT5 inhibitorok

Also Published As

Publication number Publication date
ES2967457T3 (es) 2024-04-30
FI3980417T3 (fi) 2023-12-28
SI3980417T1 (sl) 2024-02-29
CO2022000061A2 (es) 2022-04-08
MX2021015262A (es) 2022-04-06
US20220315589A1 (en) 2022-10-06
CL2021003292A1 (es) 2022-08-19
EP3980417B1 (en) 2023-09-27
HUE064493T2 (hu) 2024-03-28
CR20220010A (es) 2022-05-13
PL3980417T3 (pl) 2024-03-18
CN114026094A (zh) 2022-02-08
IL288401A (en) 2022-01-01
HRP20231673T1 (hr) 2024-03-15
KR20220019781A (ko) 2022-02-17
PT3980417T (pt) 2023-12-28
RS64972B1 (sr) 2024-01-31
PE20230245A1 (es) 2023-02-07
LT3980417T (lt) 2023-12-27
EP3980417A1 (en) 2022-04-13
ZA202109573B (en) 2022-11-30
DK3980417T3 (en) 2023-12-18
BR112021024999A2 (pt) 2022-01-25
JP2022536337A (ja) 2022-08-15
CA3141748A1 (en) 2020-12-17
AU2020293021A1 (en) 2021-12-23
WO2020250123A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
ECSP22001370A (es) Inhibidores de prmt5
EA201991884A3 (ru) Ингибиторы g12c kras
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EA202193015A1 (ru) Ингибиторы cdk
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112021011325A2 (pt) Derivados de rapamicina
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.